Breakthrough Injectable Therapy Shows Promise in Melanoma Treatment
A new injectable therapy is making headlines for its effectiveness in battling melanoma over a five-year period. This treatment, known as intismeran autogene, is a personalized mRNA cancer therapy developed in partnership with Merck and Moderna. It works alongside the immunotherapy drug KEYTRUDA (pembrolizumab).
Recent findings from the phase 2b KEYNOTE-942 study were shared at the American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago on May 27. The results showed that this combination therapy reduced the risk of melanoma recurrence or death by an impressive 49% compared to using KEYTRUDA alone.
The study followed 157 patients, all diagnosed with high-risk stage 3 and 4 melanoma, after their cancer was surgically removed. These patients were divided into two groups: one received the combination therapy, while the other only received KEYTRUDA.
Patients receiving the combined treatment enjoyed benefits that were not only immediate but also continued over time. Intismeran autogene is uniquely tailored based on mutations found in a patient’s own tumor, aiming to help the immune system recognize and target the cancer effectively.
Researchers reported that intismeran is “well-tolerated” with manageable side effects. Common issues such as fatigue, pain at the injection site, chills, fever, and headaches were observed, but there were no severe safety concerns or new long-term risks reported.
This combination therapy is now under further evaluation in a phase 3 study, which is a key step before potential widespread use.
Dr. Kyle Holen from Moderna emphasized that these findings showcase the promising potential for long-term benefits in patients dealing with high-risk melanoma. He highlighted the need for continued investment in cancer treatment innovations.
Dr. Marjorie Green from Merck reiterated the risk of recurrence for many patients after surgery, underscoring the importance of these encouraging findings.
The promising results have led to a closer look at additional trials, with expectations for significant impacts in treating various challenging cancers.
